Print

Malaria Epidemiology

  • 1a. What are (nationally) scalable novel options to conduct fine-scale monitoring of malaria burden and control progress?
    1b. Can fine-scale monitoring guide accelerate transmission reduction efforts through targeted interventions in identified transmission hot-spots?
    1c.  Can vector and host parasite genomics help elucidate transmission dynamics?
    1d. If so, how are such novel tools best implemented within the health system?
    2a. What are intervention options to optimise universal coverage and implementation of control strategies.
    2b. How important is antimalarial dose and regimen optimization within global transmission reduction efforts and emerging artemisinin and insecticide resistance?

    2c. How could dose optimization best be integrated into the global antimalarial drug development and roll-out process in order to maximize their impact and lifespan?
    1. There is increasing interest of funders, policy makers and programme implementers in targeting control and elimination efforts in line with the high heterogeneity of malaria. This is hampered by a lack of affordable, fine-scale monitoring tools.
    2. Sub-optimal dosing regimens threatens the effectiveness, safety, and therapeutic longevity of antimalarials when used in practice. With the global focus on accelerating transmission reduction, emerging artemisinin resistance, and repeated historical examples of suboptimal dosing of antimalarials, the standard drug development process needs to be tailored to optimize drugs for programmatic use earlier in the development process.
    3. Despite the implementation of effective and free interventions for the prevention of malaria in pregnancy, the uptake of the services remains sub-optimal. Understanding of the factors that influence this coverage is a way towards determining interventions that will optimize the uptake of the malaria in pregnancy prevention measures.
  • 1a. To develop and assess novel spatio-temporal sampling strategies for fine-scale monitoring (via simulations and field assessments).
    1b. To assess application of fine-scale monitoring in large-scale transmission reduction intervention trials.
    1c. To assess role of parasite genomics (host and vector) within monitoring.
    1d. To assess costs and feasibility of identified promising tools.
    2a. To develop and support targeted dose optimization study designs as viable alternatives to the standard WHO efficacy studies (via technical assistance to national control programmes).
    2b. Assess the cardiac safety of DHA-PPQ (clinical trial, PK/PD modelling and pooled analysis of individual patient data).
    3a. To explore the factors influencing uptake of the various doses of IPTp (cost factors inclusive).
    3b. To explore factors affecting the use of LLNS by pregnant women, children and other household members
    3c. Explore HCWs/Community perspectives of a community based approach on IPTp for malaria prevention in pregnant women.
    3d. To assess strategies/ways that may increase the uptake of preventive interventions for MIP.

  • Recent publication highlights(at bottom page): 1) Invited commentary on DHA-PPQ Cochrane review Hodel & Terlouw (IJE 2015);2)Weight-for-age growth references for malaria-endemic regions. Hayes & Terlouw (Bull WHO 2015); Recent grants: MCDC. Internship programme ~£100,000 (Mar 15); EDCTP. CSA award to move dose optimization trial findings into policy €500,000 (Sep 15). USAID award to support Zimbabwe control programme with novel national drug efficacy and effectiveness studies ~$400,000 (Oct 15)